32 results about "Normal pregnancy" patented technology

A one piece maternity support for the relief of discomfort associated with the progressive changes in the human body associated with a normal pregnancy. The support has a body encircling upper band for the support of the lower uterine segment and a lower belt having a pair of tensionable arms that connect to the upper band to support the lumbar region and offer counter rotational force for the anteriorly tilted pelvis. The position of the lower arms is optimized to apply a constant pressure to the muscles above the hip joint providing relief from so-called hip pain associated with many pregnancies.

The present invention provides a one-step pregnancy diagnostic device capable of simultaneously detecting and distinguishing normal pregnancy and ectopic pregnancy and a method for preparing such a device. According to the present invention, normal pregnancy and ectopic pregnancy can be quickly and accurately determined at an early stage by immunologically detecting the morphological difference between human chorionic gonadotropin (hCG) and its modified forms secreted into the body fluids of pregnant women.

The invention provides serum-based, diagnostic, biological assays for predicting disorders of pregnancy resulting from poor trophoblast and / or placental ischemia, including preeclampsia. Serum samples from such subjects exhibit an ability to disrupt the architecture involving fetal trophoblasts and maternal endothelial cells in a three-dimensional, dual cell co-culture system provided herein, in contrast to normal pregnancy serum samples. Based on these distinctions, the assays are employed to predict pregnancy outcomes as early as first trimester.

The invention belongs to the technical field of medicines, and in particular discloses application of fructose 1,6-diphosphate (FDP) in preparation of a fetus protection medicine for spontaneous abortion. In vitro and in vivo animal experiments show that the concentration of the FDP in peripheral blood and decidual tissues of patients with recurrent spontaneous abortion is decreased compared withnormal pregnancy. Compared with control pregnant mice, the model plasma and uterus FDP levels of pregnant mice with spontaneous abortion are reduced, the uterus macrophage M2 phenotype molecule expression of the pregnant mice with spontaneous abortion is decreased, the proportions of helper cells T(Th)2 and regulatory T cells are reduced, and the phenomena of poor endometrium decidualization and decreased embryonic trophoblast infiltration degree occur in an accompanied way. The results indicate that the supplement of the FDP can significantly improve the uterine immune tolerance pattern, decidualization and embryonic trophoblast infiltration in the pregnant mice with spontaneous abortion, and obviously reduces embryonic loss in the pregnant mice. Therefore, the FDP is expected to be an early-warning and diagnostic indicator for the patients with spontaneous abortion, and can be used for preparing the fetus protection medicine for the spontaneous abortion.

Raised total plasma FVII protein, including activated FVII (FVIIa) in pregnant females, compared with total plasma FVII protein in normal pregnancy, has been found to be an indicator of the pregnancy complication of pre-eclampsia.

The invention belongs to the field of biotechnology, and relates to the use of peripheral blood NK cells expressing Tim-3 in the preparation of spontaneous abortion biomarkers. The NK cells of the present invention have a tolerant phenotype and low cytotoxicity. It has been proved by experiments that the peripheral blood NK cells expressing Tim-3 are highly expressed in the peripheral blood of normal pregnancy, and the number of such cells in patients with spontaneous abortion Decline, dysfunction; Antagonizing Tim-3 of NK cells leads to pregnancy failure, and adoptive transfer of this NK cell subset can rescue immune spontaneous abortion model and pregnancy failure caused by NK knockout; the peripheral tumor expressing Tim-3 Blood NK cells can be used to prepare biomarkers of spontaneous abortion, and further serve as a new target for the prediction and prevention of spontaneous abortion of unknown clinical reasons.

The present invention relates to the application of succinic acid in diagnosis or treatment of spontaneous abortion. The present invention compared the concentrations of glycolytic and citric acid cycle metabolites in the villi and decidua of normal pregnancy and those with recurrent abortion (RSA) by metabolic mass spectrometry, and found that succinic acid was low in the villi of embryos from patients with RSA. level; in vitro succinic acid treatment can promote the proliferation and invasion of trophoblast cells HTR8 and JEG3; at the same time, in vivo experiments confirmed that succinic acid intraperitoneal injection can reduce glycine-induced spontaneous abortion mouse model and CBA / J×DBA / 2 spontaneous abortion model embryo Absorption rate, thus providing a new method for the diagnosis and treatment of RSA clinically. The present invention also reduces the level of succinic acid in mice by intraperitoneally injecting glycine, leading to an increase in the absorption rate of mouse embryos, and establishes a new spontaneous abortion mouse model that is consistent with clinical phenomena and has a clear mechanism.

The invention discloses an ovarian hyperstimulation syndrome (OHSS) detection marker Kallistatin, and also discloses an application of Kallistatin protein in screening and / or preparation of an ovarianhyperstimulation syndrome detection reagent, and the ovarian hyperstimulation syndrome detection kit. Through research, the inventor of the invention finds that Kallistatin is widely expressed in ovarian granular cells, and the expression level in cell nucleuses is higher than that in cytoplasm. The inventor finds for the first time that compared with a control group for assisted reproduction, inclinical follicular fluid specimens and serum specimens of an OHSS high-risk group, the expression of Kallistatin protein is obviously reduced; compared with a normal pregnant woman, the content of Kallistatin in serum of an OHSS patient is remarkably reduced. It is prompted that Kallistatin can be used as a specific detection marker of OHSS, is used for screening and preparing an OHSS detectionkit, and has good sensitivity and specificity. The invention provides a novel specific molecular marker for clinical detection of OHSS, and enriches the clinical detection method of OHSS.